Determination of hexamethylene bisacetamide, an antineoplastic compound, in mouse and human plasma by LC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 23, 2011, Pages 2206-2212

  Smith, Kerri M ^a   Ketchart, Wannarasmi ^b   Zhou, Xiang ^a   Montano, Monica M ^b   Xu, Yan ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Heptamethylene bisacetamide; Hexamethylene bisacetamide; HEXIM1; LC MS MS

Indexed keywords

BREAST CANCER; HEPTAMETHYLENE BISACETAMIDE; HEXAMETHYLENE BISACETAMIDE; HEXIM1; LC-MS/MS;

ACETONITRILE; DISEASES; DRUG DOSAGE; MAMMALS; MASS SPECTROMETRY; PLASMA (HUMAN); PLASMAS; SODIUM CHLORIDE; TISSUE;

CYCLOHEXANE;

ACETONITRILE; HEXAMETHYLENEBISACETAMIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CHEMICAL REACTION; COLUMN CHROMATOGRAPHY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG RETENTION; DRUG STABILITY; HUMAN; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ACETAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; MICE; TANDEM MASS SPECTROMETRY;

MUS;

EID: 79960564715     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.06.002     Document Type: Article

References (23)

1. Reuben R.C., Wife R.L., Breslow R., Rifkind R.A., Marks P.A. Proc. Natl. Acad. Sci. 1976, 73:862.
2. Marks P.A., Richon V.M., Kiyokawa H., Rifkind R.A. Proc. Natl. Acad. Sci. 1994, 91:10251.
3. Rowinsky E.K., Ettinger D.S., Grochow L.B., Brundrett R.B., Cates A.E., Donehower R.C. J. Clin. Oncol. 1986, 4:1835.
4. Egorin M.J., Zuhowski E.G., Cohen A.S., Geelhaar L.A., Callery P.S., Van Echo D.A., Forrest A. Cancer Res. 1987, 47:6142.
5. Rowinsky E.K., Ettinger D.S., McGuire W.P., Noe D.A., Grochow L.B., Donehower R.C. Cancer Res. 1987, 47:5788.
6. Young C.W., Fanucchi M.P., Declan Walsh T., Baltzer L., Yaldaei S., Stevens Y.W., Gordon C., Tong W., Rifkind R.A., Marks P.A. Cancer Res. 1988, 48:7304.
7. Rowinsky E.K., Donehower R.C., Spivak J.L., Burke P.J., Griffin C.A., Jones R.J. J. Natl. Cancer Inst. 1990, 82:1926.
8. Egorin M.J., Sigman L.M., Van Echo D.A., Forrest A., Whitacre M.Y., Aisner J. Cancer Res. 1987, 47:617.
9. Andreeff M., Stone R., Michaeli J., Young C.W., Tong W.P., Sogoloff H., Ervin T., Kufe D., Rifkind R.A., Marks P.A. Blood 1992, 80:2604.
10. Cecchinato V., Erba E., Basile A., Scarpati B., Fazi C., Brando B., Comi P., Chiaramonte R. Leuk. Res. 2008, 32:791.
11. Kusuhara K.N.M., Kimura K., Maass N., Manabe T., Ishikawa S., Aikawa M., Miyazaki K., Yamaguchi K. Biomed. Res. 1999, 20:273.
12. Wittmann B.M., Wang N., Montano M.M. Cancer Res. 2003, 63:5151.
13. Ogba N., Chaplin L.J., Doughman Y.Q., Fujinaga K., Montano M.M. Cancer Res. 2008, 68:7015.
14. Wittmann B.M., Fujinaga K., Deng H., Ogba N., Montano M.M. Oncogene 2005, 24:5576.
15. Sims R.J., Belotserkovskaya R., Reinberg D. Genes Dev. 2004, 18:2437.
16. He N.H., Pezda A.C., Zhou Q. Mol. Cell. Biol. 2006, 26:7068.
17. Li Y., Jiang S., Chen L. Chromatographia 1992, 34:63.
18. Walsh T.D., Fanucchi M.P. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 1987, 414:510.
19. Callery P.S., Egorin M.J., Geelhaar L.A., Nayar M.S. Cancer Res. 1986, 46:4900.
20. Litterst C.L., Roth J.S., Kelley J.A. Invest. New Drugs 1985, 3:263.
21. Jiang H., Jiang J., Hu P., Hu Y. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2002, 769:169.
22. Bansal S., DeStefano A. The AAPS J. 2007, 9:E109.
23. ) (accessed on 01.06.11). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.